ClustALL: A robust clustering strategy for stratification of patients with acutely decompensated cirrhosis

3 4 Sara Palomino-Echeverria, spalomie@navarra.es, Spain<sup>1</sup> 5 Estefania Huergo, ehuergoi@navarra.es, Spain<sup>1</sup> 6 7 Asier Ortega-Legarreta, aortegal@navarra.es, Spain 1 Eva M. Uson, eva.uson@efclif.com, Spain<sup>2</sup> 8 Ferran Aguilar, ferran.aguilar@efclif.com, Spain<sup>2</sup> 9 Carlos de la Pena, carlos delapena@efclif.com, Spain<sup>2</sup> 10 Cristina Lopez-Vicario, clopezv@recerca.clinic.cat, Spain<sup>3</sup> 11 Carlo Alessandria, carloalessandria@libero.it, Italy Wim Laleman, wim.laleman@uzleuven.be, Belgium<sup>5</sup> 12 13 Alberto Farias Queiroz, alberto.farias@fm.usp.br, Brazil<sup>6</sup> 14 Richard Moreau, richard.moreau@inserm.fr, France<sup>2,7,8,9</sup> 15 Javier Fernandez, javier.fernandez@efclif.com, Spain<sup>2</sup> 16 Vicente Arroyo, vicente.arroyo@efclif.com, Spain<sup>2</sup> 17 Paolo Caraceni, paolo.caraceni@unibo.it, Italy¹  $\label{thm:composition} \mbox{Vincenzo.lagani@gmail.com}, \mbox{Georgia}^{11,12,13}$ 18 19 Cristina Sanchez, cristina.sanchez@efclif.com, Spain 20 Joan Claria, jclaria@clinic.cat, Spain<sup>3</sup> 21 Jesper Tegner, jesper.tegner@kaust.edu.sa, Saudi Arabia<sup>11</sup>  $\bar{2}\bar{2}$ Jonel Trebicka, jonel.trebicka@ukmuenster.de, Germany<sup>2,14</sup>  $\overline{23}$ Narsis Kiani, narsis.kiani@ki.se, Sweden<sup>15</sup>  $\overline{24}$ Nuria Planell, nplanellpic@unav.es, Spain<sup>1, 16\*</sup> 25 Pierre-Emmanuel Rautou, pierre-emmanuel.rautou@inserm.fr, France<sup>7,17\*</sup>

#### PREDICT investigators, ACLARA investigators, DECISION investigators.

#### Affiliations:

26

27 28

29 30

31

54 55

1 2

- 1: Unit of Translational Bioinformatics, Navarrabiomed Fundación Miguel Servet, Pamplona, Spain
- 32 2: European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain

David Gomez-Cabrero, david.gomez.cabrero@navarra.es, Spain<sup>1,11</sup>

- 33 34 3: Biochemistry and Molecular Genetics Service, Hospital Clinic-IDIBAPS, Barcelona, Spain; European Foundation for the Study of Chronic Liver Failure (EF Clif) and Grifols Chair, Barcelona, Spain; CIBERehd, Barcelona, Spain; Department of 35 36 Biomedical Sciences, University of Barcelona, Barcelona, Spain
- 4: A.O.U. Città della Salute e della Scienza Torino, Torino, Italy
- 37 5: University of Leuven, Leuven, Belgium
- 38 6: Department of Gastroenterology, Hospital das Clínicas, University of São Paulo School of Medicine, Brazil
- 39 7: Université Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR, Paris, France.
- 40 8: Assistance Publique-Hôpitaux de Paris (AP-HP), France
- 41 9: Hôpital Beaujon, Service d'Hépatologie, Clichy, France
- 42 10: University of Bologna, Department of Medical and Surgical Science, Bologna, Italy
- 43 11: Biological and Environmental Science and Engineering Division, King Abdullah University of Science and Technology 44 (KAUST), Thuwal, Saudi Arabia.
- 45 12: SDAIA-KAUST Center of Excellence in Data Science and Artificial Intelligence, Thuwal, Saudi Arabia
- 46 13: Institute of Chemical Biology, Ilia State University, Tbilisi 0162, Georgia
- 47 14: Department of internal medicine B, University of Münster, Münster, Germany
- 48 15: Algorithmic Dynamics lab, Karolinska Institutet, Solna, Sweden
- 49 16: Universidad de Navarra, CIMA, Computational Biology Program, Instituto de Investigación Sanitaria de Navarra 50 (IdiSNA), 31008 Navarra, Spain.
- 51 17: Service d'Hépatologie, AP-HP, Hôpital Beaujon, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, 52 FILFOIE, ERN RARE-LIVER, Clichy, France.
- 53 \* Contributed equally.

**Abstract** 

56 57 58

59

63

66

67

68 69

71

72

74

75

77

78

79

80 81

Patient heterogeneity represents a significant challenge for both individual patient management and clinical trial design, especially in the context of complex diseases. Most existing clinical classifications 60 are based on scores built to predict patients' outcomes. These classical methods may thus miss features that contribute to heterogeneity without necessarily translating into prognostic 61 62 implications.

To address patient heterogeneity at hospital admission, we developed ClustALL, a computational 64 pipeline designed to handle common clinical data challenges such as mixed data types, missing 65 values, and collinearity. ClustALL also facilitates the unsupervised identification of multiple and robust stratifications. We applied ClustALL to a prospective European multicentre cohort of patients with acutely decompensated cirrhosis (AD) (n=766), a highly heterogeneous disease. ClustALL identified five robust stratifications for patients with AD, using only data at hospital admission. All stratifications included markers of impaired liver function and number of organ dysfunction or 70 failure, and most included precipitating events. When focusing on one of these stratifications, patients were categorized into three clusters characterized by typical clinical features but also having a prognostic value. Re-assessment of patient stratification during follow-up delineated patients' outcomes, with further improvement of the prognostic value of the stratification. We validated these findings in an independent prospective multicentre cohort of patients from Latin America (n=580).

76 In conclusion, this study developed ClustALL, a novel and robust stratification method capable of addressing challenges tied to intricate clinical data and applicable to complex diseases. By applying ClustALL to patients with AD, we identified three patient clusters, offering insights that could guide future clinical trial design.

## Introduction

82

88

89

92

93

94

97

98

99

100

101 102

103

104 105

107

108

109

110

111

112 113

114

115

116

117

118

119

120

121

122

123

124

125

Heterogeneity is a prevalent phenomenon observed in numerous diseases, including various types of 83 cancer (1), autoimmune conditions like multiple sclerosis (2), and diabetes (3)). This becomes 84 especially critical in diseases where environmental and lifestyle factors play a significant role. Acutely 85 86 decompensated cirrhosis, which refers to the rapid development of overt ascites, overt hepatic 87 encephalopathy, variceal haemorrhage, or any combination of these disorders, which often leads to nonelective admission to the hospital of patients who were previously stable (4), exemplifies significant inter-individual variability. It encompasses a range of causes of cirrhosis, comorbidities, precipitating events, clinical presentations, and outcomes (4). This clinical heterogeneity poses a 90 91 considerable challenge as it likely accounts for the diverse responses to treatment and outcomes observed in these patients (5). Therefore, we reasoned that analysing a large population of patients with acutely decompensated cirrhosis should allow us to develop stratification tools.

95 A major tool for the characterization of patient heterogeneity is the identification of patient 96 subtypes, also defined as patient stratification. Importantly, the World Health Organization has acknowledged patient stratification as a valuable approach for enhancing population health management and providing better-tailored services (6). In conceptual terms, patient stratification can be described as the process of grouping or clustering patients based on specific characteristics or patterns without relying on labelled data or information about future outcomes (7). Therefore, contrary to scores developed using classical statistical approaches based on the clinical course, stratification can capture features explaining patients' heterogeneity independently of their association with patient outcomes.

Numerous attempts have been made to identify subgroups within clinical datasets (7-9). However, 106 the lack of a universally applicable approach poses a significant challenge in the field of clustering analysis. Although there have been advancements beyond the classical k-means and hierarchical clustering methods, no general framework still allows the organization and classification of clustering methodologies in the clinical setting (10). Instead, many ad-hoc applications have been developed for specific scenarios, but their generalizability is often limited. While there is no global classification, these applications can be grouped based on specific characteristics such as managing missing values, collinearity, or mixed data (9). For instance, when handling missing data, some methods exclude samples from the analysis, potentially resulting in a loss of statistical power, while others rely on a single imputation, overlooking the potential bias that can be introduced (11). Highly correlated variables represent a challenge. Some methods exclude them, while others employ dimensionality reduction techniques such as Principal Component (PC) reduction to capture underlying lowerdimensional data patterns (12,13). However, both decisions may affect the outcome of the clustering, as sensitivity analyses are rarely conducted. Moreover, indiscriminate feature selection can inadvertently remove informative features along with noisy ones, potentially biasing the results (14). Furthermore, most clustering methodologies assume the existence of a single stratification, disregarding the possibility of having none or multiple valid alternatives for subgrouping the population (15). Interestingly, trace-based clustering methodologies have recently emerged to aid in the interpretation and validation of the identified subgroups, often requiring domain knowledge and expert input (16).

126 Additionally, the evaluation of clustering outcomes is an open problem that is based on the quality of the produced clusters. In the case of unsupervised clustering, where no preliminary classification 127 128 exists, evaluations are typically referenced against theoretical benchmarks. For instance, when 129 addressing the optimal number of clusters, various theoretical quality metrics are available such as 130 the clustering coefficient (17) or the silhouette index (18) among many others. Importantly, while 131 there is no universal methodology that excels across all scenarios for all data sets, as dictated by the 132 "no free lunch" theorem (19), there exist strategies that yield high-quality results (20-22). Another 133 essential measure-referred to as robustness-lacks a precise definition. Robustness, in general 134 terms, signifies the capacity of a system to withstand changes (23). In our context, we investigate 135 whether a clustering remains stable when subjected to perturbations. In this work, we considered 136 two types of perturbations: those derived from changes in the population and those arising from 137 changes in the algorithm's parameters. In the case of population-based perturbations, we quantify 138 how a given clustering is influenced by variations in the underlying population. Bootstrapping is one 139 approach to address this scenario (24). In the case of parameter-based perturbations, we assess the 140 impact of parameter adjustments in the clustering algorithm on the identified clustering (25). 141 Consider a scenario where a parameter "x" defines our clustering strategy. How different is the 142 resulting clustering when using "x=1" versus "x=1.1"? Here, robustness translates to clusterings that 143 maintain stability even when parameter values shift. For the reader's clarity, we will name the two 144 different robustness criteria: population-based robustness and parameter-based robustness.

Importantly, there is currently no methodology capable of addressing all the aforementioned scenarios while ensuring both definitions of robustness. To address these challenges comprehensively, we developed ClustALL, a novel framework that robustly identifies patient subgroups by addressing all the previously mentioned challenges and limitations of existing methodologies, and applied ClustALL -as a proof-of-concept- in two large prospective cohorts of patients non-electively admitted to the hospital for acutely decompensated cirrhosis.

145 146

147

148

149

150

151

152153

154

155

156

157

158

159

In this study, ClustALL was applied to a large prospective cohort of patients non-electively admitted to the hospital for acutely decompensated cirrhosis. The resulting stratifications were thoroughly characterized, aiming to identify any particular stratification of special interest in the clinical context showing prognostic value. We then validated the reproducibility of this stratification using a separate prospective cohort of patients. One further aim of the study was to demonstrate the usability of stratification over the disease course, with prognostic value.

## Results

160

161

162 163

165

171

181

183 184

185 186

187

188

189

190

# ClustALL, a robust data-driven framework for patient stratification in complex

164 We developed a specialized stratification framework, referred to as ClustALL, specifically designed to accurately identify all potential alternatives for stratifying a population using clinical multimodal data 166 at hospital admission as input. The ClustALL methodology consists of three main steps illustrated in 167 Figure 1 and detailed in the Methods section: (1) Data Complexity Reduction (depicted in the Green 168 Panel of Fig.1) aims to simplify the original dataset by mitigating the impact of redundant 169 information (highly correlated variables). As a result, we obtain a set of embeddings, each one 170 derived from different groupings of clinical variables. (2) Stratification Process (depicted in the Purple Panel of Fig.1), where, for each embedding, multiple stratification analyses are performed 172 using different combinations of distance metrics and clustering methodologies. From each 173 combination, denoted as "embedding + distance metric + clustering method", a stratification is 174 derived. (3) Consensus-based Stratifications step (depicted in the Red Panel of Fig.1) aims to identify 175 robust stratifications that, in addition, exhibit minimal variation when combination parameters 176 ("embedding + distance metric + clustering method") are slightly modified. ClustALL performs a 177 population-based robustness analysis for each stratification using bootstrapping. This analysis 178 ensures that combinations associated with non-robust stratifications are excluded. The resulting 179 stratifications are then compared using the Jaccard distance. As a result, a heatmap is generated to 180 visually identify groups of representative stratifications (green squared lines). The selection of representative stratifications enables the preservation of those stratifications that demonstrate 182 parameter-based robustness: consistency even when various parameters, like distance metrics or clustering methods, are altered. For each group of stratifications, the centroid is selected as the final stratification (green squares).

Combining these three steps allows ClustALL to identify none, or multiple robust stratifications in a given population of patients with complex diseases. Importantly, a specific implementation of ClustALL is designed to effectively handle datasets with missing data effectively, ensuring that incomplete information does not hinder the stratification process.

#### ClustALL uncovers stratification in a cohort of patients with acutely 191

decompensated cirrhosis: a proof-of-concept 192

### Study population.

193

199 200

201

202

203

204

205

207

208

209

210 211

212

213

214

215

216

217

218

219

220

221

222

223

194 The ClustALL approach was applied to a subset of individuals from the European PREDICT cohort (26), which included 766 patients with acute decompensation of cirrhosis and 74 clinical features 195 196 collected at hospital admission, with less than 30% missing values. Complete information on patient 197 characteristics and short-term outcomes, including acute-on-chronic liver failure (ACLF), liver 198 transplant, and death, can be found in Supplemental Table 1.

#### ClustALL identified five different alternatives to stratify the population.

The ClustALL workflow was utilized to discover potential new sub-phenotypes of patients with acute decompensation of cirrhosis within the PREDICT cohort upon hospital admission (Fig.2). To handle missing values in the dataset, we employed the ClustALL framework, which incorporates imputations using 1,000 iterations, as described in the Methods section. The Data Complexity Reduction Step resulted in 72 embeddings (Fig.2.1). The Stratification Process generated 288 stratifications based on the different combinations of "embedding + distance metric + clustering method" (Fig. 2.2). Among these, 144 population-based robust stratifications were identified through the Consensus-based Stratifications step, resulting in five groups of parameter-based representative stratifications. The centroid was selected for each group of stratifications, (Fig.2.3).

#### ClustALL provides better resolution than classical clustering tools

We conducted an analysis to assess the added value of ClustALL when compared with classical clustering methodologies such as k-means or hierarchical clustering. Regarding the classical methodologies, our findings revealed that when using correlation as a distance metric, 90% of patients were consistently assigned to a single cluster, regardless of the number of clusters considered; when Gower distance was utilized, the distribution of patients across clusters presented a more balanced distribution (Table S2). Notably, the population-based robustness of the stratifications generated by ClustALL was significantly higher (p-value < 0.01) compared to the results obtained using k-means and hierarchical clustering (Fig.S3). In summary, our observations demonstrate that ClustALL significantly outperforms classical methodologies regarding populationbased robustness.

#### Characterization of the five robust stratifications within the PREDICT population

224 After identifying the robust stratifications, we aimed to explore and characterize the distinct clusters 225 observed in each of the five alternative stratifications. These stratifications divided the patients into 226 two clusters, except for stratification 1, which had three clusters. We visually investigated the 227 separation by representing each stratification in a low-dimensional space using the corresponding 228 embeddings derived from the dendrogram depths (Fig.3A-E) and the complete dataset (Fig.S2). 229 Further exploration revealed that stratification 1 was a subdivision of stratification 2 (Fig.3F). We 230 then determined the minimal sets of variables (excluding the cirrhosis severity scores (Table S1 231 variables 44 to 48)) with the highest predictive performance in differentiating the clusters for each 232 stratification (Tables S3-S7) (27). The different classification approaches were described by 25 233 variables from a total of 74 (Table S1 variables 1 to 74), with 8 to 12 variables per stratification 234 (Fig.4A). Notably, all stratifications included: (i) serum bilirubin concentration (either as a continuous

variable or categorized under the term "liver dysfunction" (28)) (ii) International Normalized Ratio (INR) (either as a continuous variable or categorized under the term "coagulation dysfunction" (28); (iii) the number of organ dysfunction or failure. Precipitating events were present in all but one 238 stratification (stratification 3) either as a sum or individually (gastrointestinal bleeding, alcohol-related hepatitis, acute viral hepatitis). Diabetes mellitus was included in two stratifications. Conversely, age, sex, BMI, cause of cirrhosis and lifestyle were present in no or one stratification. Interestingly, stratification 1 and 2 shared almost the same minimal set of variables. Both stratifications identified a group of patients with a severe phenotype attested by low serum sodium, low serum albumin, high serum bilirubin, high INR, high C-Reactive Protein (CRP) and leucocytes, and the number of precipitating events (Fig.4B). Hepatic encephalopathy was present in stratification 1 but not in 2 (29). A complete statistical characterization of the stratifications is provided in Tables S3 to S7. Considering the clinical implications of the features and the finer classification of the patients, we identified stratification 1 as the most insightful for further exploration in patients with acute decompensation of cirrhosis. Henceforth, in our discussions, we will refer to this specific stratification as 'AD-strat'.

#### AD-strat provides prognosis value

The *AD-strat* stratification is defined by three subgroups (clusters) of patients with acutely decompensated cirrhosis revealing different clinical characteristics and disease progression. Cluster 1 included 306 patients (39.95%) who exhibited the most clinically critical scenario (Fig.5A, B and Table S3). These individuals had the highest rates of organ dysfunction, clinical events, and precipitating events (Table S1). They had a marked acute inflammatory profile (high white blood cell count, and C-reactive protein level) poor liver function (low levels of albumin, and high levels of INR and serum bilirubin) and more hepatocyte injury (higher levels of serum aspartate aminotransferase). Conversely, Cluster 2 (n=118; 15.4%) and Cluster 3 (n=342; 44.6%) had a less severe presentation. The main difference between Cluster 2 and 3 was hepatic encephalopathy, found in 89% of the patients in Cluster 2 and almost no patients in Cluster 3 (Fig.5A, B and Table S2). Importantly, a significant prognostic value of *AD-strat* was revealed by exploring the cumulative incidence of ACLF and death over 90-day follow-up (Fig.5C). Patients in Cluster 1 had poor short-term outcome, with a cumulative incidence of ACLF and death, both by 90 days of 24.1 and 21.5, respectively. While Clusters 2 and 3 had similar risks of ACLF by 90 days (8.6% and 10.2 %, respectively), the risk of death by 90 days was lower for Cluster 2 than Cluster 3 (4.3% vs 10.7%).

When we compared the clusters identified with ClustALL - exclusively using data obtained at admission - with the groups of patients based on their clinical course (26), we found a statistically significant association (Fisher test, p-value < 0.01) (see **Table S8**). We observed that 61% of patients with pre-ACLF were in Cluster 1 and 48% of patients with stable decompensated were in Cluster 3.

## Reproducibility of the stratification model in an independent cohort

We assessed the validity of the *AD-strat* model in a large independent prospective multicentre cohort that included 580 patients with acute decompensation of cirrhosis from the Latin-American ACLARA study (30). Using as a reference the PREDICT *AD-strat* clusters, we labelled ACLARA patients using the k-nearest neighbours (kNN) classification algorithm (**Table S9**) (31). The classification model included the 12 predictive variables previously identified in the feature importance analysis

280 (Fig.3B Stratification 1). Importantly, the labelling was consistent and independent of the imputation 281 (Fig.6A), and the distribution of individuals by AD-strat clusters within ACLARA closely mirrored that 282 of the PREDICT cohort (Fig.6B). As expected, the clustering of the ACLARA cohort exhibited similar 283 clinical feature patterns to the PREDICT cohort (Fig. 6C, Fig. 3B Stratification 1). Furthermore, the 284 features describing the subgroups demonstrated statistical significance (Table S10). Finally, we 285 assessed the clinical relevance of the clustering in terms of prognosis, specifically examining the 286 short-term outcomes available in the ACLARA cohort 28 days after hospital admission. Similar to 287 results obtained in the PREDICT cohort, Cluster 1 displayed a bad prognosis for both ACLF and death, 288 while Cluster 3 showed a better prognosis (Fig.6D). In ACLARA, all patients from Cluster 2 were 289 afflicted by hepatic encephalopathy (Table S10) and showed a poor prognosis similar to that of 290 Cluster 1. Ethnicity was homogeneously distributed across clusters (Table S2). In particular, Native Americans represented 21% of Cluster 1, 15% of Cluster 2, and 14% of Cluster 3. Complete 292 information on patient characteristics and short-term outcomes is reported in Supplemental Table 293

## AD-strat as a marker for clinical management

291

294 295

296 297

298

299

300

301

302

303 304

305

306

307

308 309

310

311

312

313

314

315

316

317

318

319

320 321

322

323

324

Finally, we investigated the clinical value of the stratification during the follow-up visits of the PREDICT cohort. Based on the PREDICT study design (26), two follow-up visit plans were established depending on the reported disease severity (CLIF-C AD-score) at hospital admission (Fig. 7A). For patients with a CLIF-C AD-score ≥ 50, the scheduled visits were performed at hospital admission and 1, 4, 8 and, 12 weeks after enrolment. For patients with a CLIF-C AD-score < 50, the scheduled visits were performed only at hospital admission and 1 and 12 weeks after enrolment.

Of the 766 patients included in the PREDICT study, 688 had at least one follow-up visit. For this subset of patients with available data, we labelled each of them at each follow-up visit using the kNN algorithm (Fig. 7B). This approach allowed an overview of the patient stratification over the entire study duration and revealed the patient flow over time highlighting cluster transitions.

Consistent with the previous AD-strat characterization at hospital admission (Fig.5 and Table S3), we identified more than 50% of patients with CLIF-C AD score ≥ 50 (n=486) were classified as Cluster 1, while patients with CLIF-C AD score < 50 (n=280) were predominantly classified as Cluster 3 (66.4%) (Fig.7B). Changes in cluster proportions were observed during the patients' follow-up. Stratification changes over time were more pronounced among patients with CLIF-C AD scores≥ 50 at hospital admission, showing a progressive reduction of patients classified as Cluster 1 (55.8% at HA, 38.8% at week 1, 39.2% at week 4, 25% at week 8, and 17.1% at week 12) and an increase of those classified as Cluster 3 (32.1% at HA, 54.6% at week 1, 50.9% at week 4, 67.9% at week 8, and 74.3% at week 12). Additionally, there was a progressive increase in the proportion of patients classified as Cluster 3 for those patients with CLIF-C AD-score < 50 at hospital inclusion (66.4% at HA, 83.3% at week 1, and 82.5% at week 12).

To assess the effectiveness of the AD-strat throughout disease progression, we determined its prognostic value in two scenarios: 1) using the stratification at hospital admission, and 2) using the stratification at the last visit reported before the occurrence of any adverse event (we considered any visit between week 1 and 12) or at the end-of-study (EOS) (week 12 visit). A significant

325

326 327

328

330

331

332

333

334

335 336

difference was observed (p<0.001, Wilcoxon test) when comparing the time window between the visit used in each scenario and the occurrence of adverse events (Fig. S5), indicating that in the second scenario, we evaluated patients during a visit much closer to the event. 329 Ultimately, the cumulative incidence of ACLF and death as stratified at the last visit demonstrated a more significant separation between clusters compared to patient stratification at hospital admission (Fig.8). There was an increase in the incidence for those patients classified as Cluster 1 (18.46% and 18.45% at baseline and 28.16% and 26.8% at the last visit for ACLF and death, respectively). Accordingly, the goodness-of-fit parameters indicated an improvement in risk prediction with the last visit stratification, suggesting an enhanced predictive power as the event approached (Table S11).

## Methods

337 338

343 344

347

348

349 350

351

352

353

354

355

356

357

358

359

360

361

362 363

364

365

366

367

368

369

370

371

372

373

374

375

376 377

378

379

380

#### ClustALL Framework

339 Given a set of patients affected by a complex disease with clinical data available, the goal of ClustALL 340 is to identify all the possible alternatives to stratify them that are robust and consistent, even when 341 different parameters or settings are used to generate the stratifications (distance metric, clustering 342 algorithm, and the number of imputations).

#### Input data

345 ClustALL accepts both binary and numerical clinical variables as input. Categorical features are 346 transformed using a one-hot encoder method. A minimum of two features is required, but including more features would lead to more precise clustering. It is important to note that increasing the number of features may also increase the computation time.

## Step 1. Data Complexity Reduction

In this step, highly correlated features are replaced by a reduced set of variables that account for their variability. To that end:

Step 1.1. Dendrogram. Hierarchical clustering is applied to the data, resulting in a dendrogram where variables are grouped based on similarity (32). The depth of each branch represents the distance between the groups of variables. All the possible depths of the dendrogram are extracted, and the sets of variables beneath each depth are stored as Depth.

Step 1.2. Preprocessing. Principal Component Analysis (PCA) is computed for each set of variables corresponding to each Depth, and the first three principal components are stored in a new matrix (Embedding) (33). For sets that contain only one variable, the variable itself is stored to generate the replacement matrix. This results in a complexity-reduced data set (Embedding) for each considered Depth. A subset of depths can be considered when the number of variables is too large.

#### Step 2 Stratification Process

In this step, ClustALL calculates and pre-evaluates stratifications for each Embedding. For each Embedding, the dissimilarity between patients' pairs is computed using correlation-based distance and Gower dissimilarity metric, resulting in two distance matrices. Clustering algorithms are then applied (34-36) depending on the distance used: k-means and hierarchical clustering for correlation distance matrices, and k-medoids and hierarchical clustering for the Gower distance matrix. Throughout all experiments, five different cluster numbers are evaluated  $k \in \{2, 3, 4, 5, 6\}$ . The optimal number of clusters for each strategy is determined based on the consensus from three different measures of clustering internal validation: the sum-of-squares based index or WB-ratio, the Dunn index, and the average silhouette width (37,38). The objective is to group patients with comparable data while ensuring that patients in separate clusters are as dissimilar as possible from those in other clusters. As the output for this step, a stratification is derived for each combination denoted as "embedding + distance metric + clustering method".

## Step 3 Consensus-based stratifications

Step 3.1. Population-based robustness. A data-driven threshold is used to define population-based robust subgroups or clusters. For each resulting stratification from the previous step, cluster-wise stability is computed by bootstrapping the dataset 1,000 times and calculating the

Jaccard similarity index to the originally defined clusters (39). Stratifications with less than 85% stability (**Fig.S4**) are excluded based on data distribution. The remaining stratifications are denoted as *Strat*<sub>filt</sub>.

Step 3.2. Jaccard distance is applied to compute distances between the population-based robust stratifications. Then, to identify parameter-based robust clusters (where a minor modification in parameter selection provides a similar result), ClustALL considers those combinations that are part of a group of stratifications (green squares in Consensus-based stratifications step in Fig.1). Then, as initial criteria, that can be modified by the user, centroids from each "combination group" are selected as parameter-based robust stratifications (coloured green squares in Consensus-based stratifications step in Fig.1). The outcome can be none, one, or multiple ways to stratify the population robustly. In the current analysis, we considered parameter-based robust representatives: centroids of a combination group that includes at least 5 population-based robust stratifications.

#### ClustALL enables input data with missing values

395 ClustALL can be adapted to work with missing data (Fig.S1). To that end, the ClustALL method is 396 modified as follows:

<u>Step 1 adaptation</u>. First, a dendrogram and its associated depths are computed considering the original dataset with missing values. The original dataset is then imputed 1,000 times with the MICE algorithm to ensure the results are not derived from a single imputation (40). For each *Depth previously calculated* and each imputed dataset, the Data Complexity Reduction step is applied.

401 Step 2 adaptation. Step 2.1 is computed for each combination of depth, distance metric, clustering 402 algorithm and each Embedding derived from an imputed dataset. The selection of the optimal 403 number of clusters is based on the consensus from cluster internal validation and the mode of the 404 imputed datasets for each corresponding embedding. Afterward, a distance matrix  $(D_{mat})$  between 405 individuals is obtained by computing how often two individuals are assigned to the same cluster in 406 each imputation (Fig.S1). Then,  $D_{mat}$  calculates a final stratification score using correlation-based 407 distance and h-clust. In our experience, limited optimization is required here because summarizing 408 the stratification over all imputations separately strengthens what is observed in each imputed 409 dataset. Extra care will be required only in cases where imputations may differ significantly. After 410 this modification, the method follows as previously described (Fig.S1).

#### Data source

381

382

383

384

385

386

387

388

389

390

391

392

393394

397

398

399

400

411412

413 The data utilized in this study were obtained from two independent multicentre studies: the 414 European PREDICT cohort and the Latin-American ACLARA cohort, conducted as part of the European 415 Project DECISION (26,41). Both cohorts collected various measures including clinical, 416 pharmacological, biomarker, and outcome data from patients with acute decompensation of 417 cirrhosis upon hospital admission and during follow-up visits. The follow-up period was 90 days for 418 the PREDICT cohort and 28 days for the ACLARA cohort. To be eligible for the present study, patients 419 were required to have acute decompensation of cirrhosis upon hospital admission, with available 420 information on short-term outcomes, drug intake, and available biological samples. Ultimately, 766 421 patients from the PREDICT cohort and 580 patients from the ACLARA cohort and 74 features 422 (continuous and categorical) were included in the analysis. The features included demographic 423 information, clinical and laboratory data, medical history, risk factors, and cirrhosis scores at hospital 424 admission, with missing values accounting for less than 30% (Table S1). To avoid bias from missing 425 data, imputation was performed with 1,000 iterations using the Multivariate Imputation by Chained

#### 426 Equations (MICE) method (21).

Demographics	Age, sex, height <sup>+</sup> , weight <sup>+</sup> , BMI, ethnicity (Black or African American, Asian, White, other)
Cause of cirrhosis	Alcohol, viral, alcohol + viral, NASH, cryptogenic, other
Main reason for hospitalization	Ascites, hepatic encephalopathy, gastrointestinal bleeding, spontaneous bacterial peritonitis, other infection
Manifestations at admission	Clinical Events (ascites, hepatic encephalopathy, gastrointestinal bleeding, acute kidney injury, bacterial infection, acute alcoholic-steatohepatitis, acute viral hepatitis, hepatocellular carcinoma), number of clinical events (the sum of clinical events), number of precipitating events (the sum of precipitating events: proven bacterial infection, acute alcoholic-steatohepatitis, CLIF-C AD > 50), organ dysfunction (liver, renal, cerebral, coagulation, cardiac, respiratory), number of organ dysfunctions (the sum of organ dysfunctions), organ failure (liver, cerebral, coagulation, cardiac, respiratory), number of organ failures (the sum of organ failures)
Cirrhosis Severity Scores	Child-Pugh, CLIF-C AD, CLIF-C OF, MELD, MELDNA
Medical history	History of diabetes, history of hypertension, history of previous decompensations
Lifestyle	Alcohol, active alcohol consumption <sup>+</sup> , tobacco
Laboratory variables (measured in serum)	Alanine transaminase, aspartate aminotransferase, albumin, bilirubin (total), gamma-GT, C-reactive protein, sodium, potassium, glucose <sup>†</sup> , hemoglobin, hematocrit, creatinine, white blood cell count, lymphocytes, monocytes, neutrophils, INR (International Normalized Ratio), platelet, SpO2 (%), SpO2/FiO2 Ratio

**Table 1. Complete list of input features.** Patient characteristics included in the analysis: demographics, cause of cirrhosis, main reason for hospitalization, manifestations at admission, cirrhosis severity scores, medical history, lifestyle and laboratory variables. \*Variables not included in ACLARA cohort.

## CLustALL comparison to different clustering methodologies

A comparison was conducted between the ClustALL framework and classical clustering algorithms. Stratification was performed on 1,000 imputed datasets using classical k-means and hierarchical methodologies with k values of 2 and 3, considering that ClustALL robust stratifications comprised two or three patient subgroups. Bootstrapping was performed for the classical clusters to evaluate cluster-wise stability (39). The resulting stability was compared to ClustALL stability through the Kolmogorov–Smirnov test. Moreover, the clinical utility of the various stratifications was assessed by examining the clinical insights obtained from the different clusters.

Statistical Methods

- 441 All analyses were performed in the R Computing Environment version 4.0.3 (42).
- 443 Descriptive statistics
- 444 Descriptive characteristics of the PREDICT and ACLARA study populations were reported as means
- 445 with standard deviations for continuous variables and proportions of patients for categorical
- 446 variables.

440

442

- 447 Feature Analysis
- 448 The identification of the minimal-size predictive signatures with maximal predictive power leading to
- 449 each stratification was performed using the fbed.reg function with default hyperparameters from
- 450 the 'MXM' R package (27).
- 451 Parametric Tests
- 452 Differences between clusters in the PREDICT and in the ACLARA cohorts were assessed using one-
- 453 way ANOVA for continuous variables, while binary variables were tested with the chi-square test.
- 454 The association between the PREDICT clusters identified with ClustALL exclusively using data
- 455 obtained at admission with the groups of patients based on their clinical course (26), was tested
- 456 with the Fisher test.
- 457 Stratification model reproducibility
- 458 AD-strat model was validated in and in a separate cohort of patients with acute decompensation of
- 459 cirrhosis from the ACLARA cohort and in PREDICT follow-up time points. For this purpose, the kNN
- 460 model was trained on the PREDICT AD-strat cluster labels based on the signatures previously defined
- as most predictive in the feature analysis. The K parameter was selected based on accuracy, the area
- 462 under the curve (AUC), error rate (ER), false positives (FP), and false negatives (FN) (**Table S7**). After
- 463 applying the KNN algorithm, the target data (ACLARA cohort and PREDICT follow-up) was labelled
- 464 based on the majority votes from the K nearest neighbours and imputed datasets.
- 465 Survival Analysis

470

- 466 Cumulative incidences of ACLF development and liver-related death were estimated using the
- 467 cumulative incidence function of the 'survival' R Package. Liver transplantation was considered a
- 468 competing event. A p-value lower than 0.05 with Benjamini and Hochberg (BH) adjustment was
- 469 considered statistically significant.
- 471 Longitudinal analysis and model evaluation
- 472 All PREDICT patients with ≥1 post-baseline assessment (n = 688) were included in longitudinal
- 473 outcomes analyses for a period of 90 days after hospital admission. Sankey diagrams were
- 474 generated to show the patients' transfers among the AD-strat clustering, liver transplant, ACLF
- 475 development, death and survival status. The predictive power of the stratification models at
- 476 different time points in the PREDICT cohort was evaluated using BIC, AIC, Concordance, and
- 477 Likelihood ratio goodness-of-fit parameters (41).

## Discussion

479 480 481

482

483

484

485 486 487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509 510

511

512

513

514

515

516

517

518

519

521

522

523

Traditional patient classification methods based on outcome prediction scores may overlook important heterogeneity factors. To address this issue, we developed ClustALL, a computational pipeline that handles various clinical data challenges and identifies robust patient stratifications. We applied ClustALL to a cohort of patients with acute decompensation of cirrhosis, identifying five robust stratifications with prognostic value.

Optimal patient stratification is required to sustain the precision medicine revolution occurring in the clinical setting (43). While significant progress has been made in classification problems, particularly in domains like single-cell transcriptomic analysis (44,45), unsupervised clustering of patients based on clinical information is still in the developmental stage (7,46). Notably, the existing challenges in clinical stratification are often addressed using ad-hoc solutions that consider mixed data types, missing values, or highly correlated variables. However, no comprehensive method currently exists that addresses all these challenges. To overcome the aforementioned idiosyncrasies in clinical data, we have developed a novel computational framework named ClustALL. Significantly, beyond addressing existing challenges, ClustALL improves over other existing methodologies by allowing the identification of more than one robust stratification within a given population. Clinical data is complex and allows for multiple uses and "multiple interpretations" that may result in several valid groupings (47). Indeed, the concept of "multiple interpretations" arises from how variables are utilized in the clustering process and has been a subject of research in the early 21st century (48). Another distinctive feature of ClustALL is the consistency of the resulting representative stratifications even when limited modifications in the clustering parameter settings are applied. In the context of biological data, such as gene expression data, this property has already been already defined as the "propensity of a clustering algorithm to maintain output coherence over a range of settings" (49). Interestingly, this definition has been applied in the study of exposome and pregnancy-related mortality in the United States (50). In summary, we believe that ClustALL represents one of the initial necessary steps towards incorporating two necessary features into clinical stratification: parameter-based robustness and the identification of more than one stratification.

To assess the effectiveness of ClustALL, we applied it as a proof-of-concept in a cohort of patients with acutely decompensated cirrhosis considering data collected at hospital admission. Such an attempt to apply stratification to patients with cirrhosis has never been conducted. The stratification we set up differs from the scores developed and routinely used in patients with cirrhosis (e.g., MELD, MELD-Na, Child-Pugh, CLIF-C-AD) both in terms of design and use. Indeed, all these scores were built using a follow-up endpoint (usually death) in patients receiving therapies. These scores are helpful to identify patients at high risk of poor outcomes, but they do not fully capture the heterogeneity of the patients at admission for several reasons: (a) some features explaining patients heterogeneity might not have an independent prognostic value, either because the prognostic information they carry is contained in other variables, or because therapies administered to patients during their 520 follow-up blunt their impact; (b) a similar survival rate does not imply similar pathophysiological mechanisms. For instance, in PREDICT, clusters 2 and 3 have a similar rate of ACLF, while they strongly differ with regard to the prevalence of hepatic encephalopathy. The stratification presented here is not intended to guide clinical bedside decisions or to replace a prognostic score but rather to

identify homogeneous patient populations at hospital admission. This stratification could base the development of future clinical trials including more homogeneous patient populations. In this 526 regard, to make this stratification easily accessible to all, we developed an online calculator and application available at https://decision-for-liver.eu/for-scientists/clustall-web-application/. The purely data-driven approach and the development and independent validation of the stratifications in large prospective multicentre European and Latin American cohorts strengthen our results.

524

525

527

528

529

530 531

532

535

537

539

541

543

544

547

548

550 551

552

553

554

555 556

557

558

559

560

561

562 563

564

565

567

568

Through this analysis, as a first step, we identified five alternative stratifications for patients with acute decompensation of cirrhosis. Interestingly, all stratifications included markers of impaired liver 533 function, namely serum bilirubin and INR, but also the number of organ dysfunction or failure, and 534 all but one included precipitating events. This emphasizes that these features are crucial when designing a clinical trial including patients with acute decompensation of cirrhosis. On the contrary, 536 some features like age, sex, BMI, cause of cirrhosis and lifestyle were present in no or only one stratification suggesting that these features are not key when designing a clinical trial. The 538 stratification we selected (AD-strat) provided a more granular resolution by allowing the identification of three subgroups of patients. In this stratification, diabetes mellitus is taken into 540 account. While it is known that diabetes is an independent risk factor for cirrhosis decompensation (51,52), the role of diabetes once acute decompensation has happened has been overlooked so far. 542 This place of diabetes is quite unique since causes of cirrhosis, comorbidities or lifestyle were not part of the key features of AD-strat. Hepatic encephalopathy strongly impacted the categorization of patients with acutely decompensated cirrhosis. Notably, 89% and 100% of the patients in Cluster 2 545 from the PREDICT and ACLARA cohorts, respectively, presented hepatic encephalopathy at the time 546 of hospital admission. This may explain the intermediate prognosis observed in patients within Cluster 2, as hepatic encephalopathy is recognised by its fluctuating nature and potential reversibility (53,54). The dynamic nature of hepatic encephalopathy may also explain why Cluster 2 549 was not a static group over time (55).

Furthermore, tracking patients over time using AD-strat labelling allowed for dynamic and improved identification of patients at high risk of adverse events in the PREDICT cohort. These results highlight the ability of the ClustALL not only to stratify patients using baseline characteristics but also that the use of AD-strat labelling over time is able to improve this prediction.

Although our study showed promising results, it is important to acknowledge some limitations. Firstly, our stratification was based solely on routinely available clinical data at hospital admission, which may not provide a comprehensive view of patients' conditions. Future studies should extend our findings with biological data, ideally derived from multiomic analyses. Moreover, it is crucial to consider that the predictive power in the ACLARA cohort was only assessed at 28 days due to the study design.

In conclusion, this study introduces a novel unsupervised clustering framework, ClustALL, able to overcome the limitations of previously available stratification methods. ClustALL is available as OpenSource (https://github.com/TranslationalBioinformaticsUnit/ClustALL AD/). When applied to 566 the setting of acute decompensation of cirrhosis, ClustALL enhanced our understanding of patients' heterogeneity emphasizing the importance of liver function and the number of organ dysfunctions or failures, precipitating events, and conversely the limited role of age, sex, BMI, cause of cirrhosis

and lifestyle at this stage of the liver disease. The selected stratification, AD-strat, might be a useful

570 tool to better design future clinical trials by including more homogeneous patient populations.

## Data availability

571

573

575

576

577

578 579 580

581

582 583

584

585

586

587

588

589

600

605

611

612 613

572 Researchers who provide a methodology sound proposal can apply for the data, as far as the proposal is in line with the research consented by the patients. These proposals should be requested 574 through https://www.clifresearch.com/decision/Home.aspx. Data requestors will need to sign a data transfer agreement. The code to generate the ClustALL method is available on GitHub, at https://github.com/TranslationalBioinformaticsUnit/ClustALL AD/.

## Acknowledgements

This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 847949.

The study was supported by the European Foundation for the Study of Chronic Liver Failure (EF-Clif). The EF-Clif is a nonprofit private organization. The EF-Clif receives unrestricted donations from Cellex Foundation and Grifols. EF-Clif is partner, contributor and coordinator in several EU Horizon 2020 program projects. JT was appointed as visiting Professor in EF-Clif for the execution of the study by a grant from Cellex Foundation. The funders had no influence on study design, data collection and analysis, decision to publish or preparation of the manuscript.e fact that EF-CLIF.

590 Jonel Trebicka was supported by the German Research Foundation (DFG) project ID 403224013 -591 SFB 1382 (A09), by the German Federal Ministry of Education and Research (BMBF) for the DEEP-592 HCC project and by the Hessian Ministry of Higher Education, Research and the Arts (HMWK) for the 593 ENABLE and ACLF-I cluster projects. The MICROB-PREDICT (project ID 825694), DECISION (project ID 594 847949), GALAXY (project ID 668031), LIVERHOPE (project ID 731875), and IHMCSA (project ID 595 964590) projects have received funding from the European Union's Horizon 2020 research and 596 innovation program. The manuscript reflects only the authors' views, and the European Commission 597 is not responsible for any use that may be made of the information it contains. The funders had no 598 influence on study design, data collection and analysis, decision to publish, or preparation of the 599 manuscript.

601 by a Ramón y Cajal fellow (RYC2021-032197-I) from N.P.P was funded 602 MCIN/AEI/10.13039/501100011033 and European Union "NextGenerationEU"/PRTR and by a Juan 603 de la Cierva-formación fellow (FJC2019-042304-I) from the Spanish Ministry of Science and 604 Innovation (MCIN).

606 P-E.R.'s research laboratory is supported by the Foundation pour la Recherche Médicale (FRM 607 EQU202303016287), "Institut National de la Santé et de la Recherche Médicale" (ATIP AVENIR), the 608 "Agence Nationale pour la Recherche" (ANR-18-CE14-0006-01, RHU QUID-NASH, ANR-18-IDEX-0001, 609 ANR-22-CE14-0002) by « Émergence, Ville de Paris », by Fondation ARC and by the European Union's 610 Horizon 2020 research and innovation programme under grant agreement No 847949.

## **Bibliography**

- 614 1. Almendro V, Kim HJ, Cheng YK, Gonen M, Itzkovitz S, Argani P, et al. Genetic and 615 phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar 616 1;74(5):1338–48.
- Kotelnikova E, Kiani NA, Abad E, Martinez-Lapiscina EH, Andorra M, Zubizarreta
   I, et al. Dynamics and heterogeneity of brain damage in multiple sclerosis. PLoS
   Comput Biol. 2017 Oct 1;13(10).
- Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019 Jun 1;7(6):442–51.
- de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al.
   Baveno VII Renewing consensus in portal hypertension. Vol. 76, Journal of
   Hepatology. Elsevier B.V.; 2022. p. 959–74.
- Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-Chronic
   Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute
   Decompensation of Cirrhosis. Gastroenterology. 2013 Jun;144(7):1426-1437.e9.
- 630 6. Cerezo Cerezo J& ALC. Population stratification: a fundamental instrument used for population health management in Spain: good practice brief. World Health Organization Regional Office for Europe https://apps.who.int/iris/handle/10665/345586. 2018;
- Moral TT, Sanchez-Niubo A, Monistrol-Mula A, Gerardi C, Banzi R, Garcia P, et al.
   Methods for Stratification and Validation Cohorts: A Scoping Review. Vol. 12,
   Journal of Personalized Medicine. MDPI; 2022.
- Horne E, Tibble H, Sheikh A, Tsanas A. Challenges of clustering multimodal clinical data: Review of applications in asthma subtyping. Vol. 8, JMIR Medical Informatics.
   JMIR Publications Inc.; 2020.
- Wang H, Donoho D, Kuppler C, Loftus TJ, Jr UG, Copyright frai, et al. Phenotype clustering in health care: A narrative review for clinicians.
- 542 10. Saxena A, Prasad M, Gupta A, Bharill N, Patel OP, Tiwari A, et al. A review of clustering techniques and developments. Neurocomputing. 2017 Dec 6;267:664–81.
- Cismondi F, Fialho AS, Vieira SM, Reti SR, Sousa JMC, Finkelstein SN. Missing data in medical databases: Impute, delete or classify? Artif Intell Med. 2013
   May;58(1):63–72.
- Rodríguez AH, Ruiz-Botella M, Martín-Loeches I, Jimenez Herrera M, Solé-Violan
   J, Gómez J, et al. Deploying unsupervised clustering analysis to derive clinical
   phenotypes and risk factors associated with mortality risk in 2022 critically ill
   patients with COVID-19 in Spain. Crit Care. 2021 Dec 1;25(1).
- Curtis JR, Weinblatt M, Saag K, Bykerk VP, Furst DE, Fiore S, et al. Data-Driven
   Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's
   Rheumatoid Arthritis Sequential Study Registry. Arthritis Care Res (Hoboken). 2021
   Apr 1;73(4):471–80.
- Pudjihartono N, Fadason T, Kempa-Liehr AW, O'Sullivan JM. A Review of Feature
   Selection Methods for Machine Learning-Based Disease Risk Prediction. Frontiers in
   Bioinformatics. 2022 Jun 27;2.
- 658 15. Hennig C. What are the true clusters? Pattern Recognit Lett. 2015 Oct 15;64:53–62.
- Lopez-Martinez-Carrasco A, Juarez JM, Campos M, Canovas-Segura B. A
   methodology based on Trace-based clustering for patient phenotyping. Knowl Based
- 661 Syst. 2021 Nov 28;232.
- Chalancon G, Kruse K, Babu MM. Clustering Coefficient. In: Encyclopedia of
   Systems Biology. New York, NY: Springer New York; 2013. p. 422–4.

- Rousseeuw PJ. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math. 1987 Nov;20:53–65.
- Adam SP, Alexandropoulos SAN, Pardalos PM, Vrahatis MN. No Free Lunch
   Theorem: A Review. In 2019. p. 57–82.
- Milligan GW, Cooper MC. An examination of procedures for determining the number of clusters in a data set. Psychometrika. 1985 Jun;50(2):159–79.
- 570 21. Steinley D, Brusco MJ. Choosing the number of clusters in K-means clustering. Psychol Methods. 2011;16(3):285–97.
- 672 22. Altman N, Krzywinski M. Clustering. Nat Methods. 2017 Jun 30;14(6):545–6.
- 673 23. Kitano H. Towards a theory of biological robustness. Mol Syst Biol. 2007 Jan 18;3(1).
- Yu H, Chapman B, Di Florio A, Eischen E, Gotz D, Jacob M, et al. Bootstrapping
   estimates of stability for clusters, observations and model selection. Comput Stat.
   2019 Mar 28;34(1):349–72.
- Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24;20(S15):503.
- Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol. 2020 Oct 1;73(4):842–54.
- Tsagris M, Tsamardinos I. Feature selection with the R package MXM. F1000Res. 2018 Jan 1;7:1505.
- 685 28. Arroyo V, Moreau R, Jalan R. Acute-on-Chronic Liver Failure. New England Journal of Medicine. 2020 May 28;382(22):2137–45.
- 587 29. Stewart CA, Malinchoc M, Kim WR, Kamath PS. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transplantation. 2007 Oct;13(10):1366–71.
- Farias AQ, Vilalta AC, Zitelli PM, Pereira G, Goncalves LL, Torre A, et al. Genetic
   Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.
   Gastroenterology [Internet]. 2023 May; Available from:
   https://linkinghub.elsevier.com/retrieve/pii/S0016508523008065
- 694 31. Deng Z, Zhu X, Cheng D, Zong M, Zhang S. Efficient kNN classification algorithm for big data. Neurocomputing. 2016 Jun 26;195:143–8.
- Schonlau M. Visualizing non-hierarchical and hierarchical cluster analyses with clustergrams. Vol. 19, Computational Statistics. 2004.
- Ringnér M. What is principal component analysis? [Internet]. Vol. 26, NATURE
   BIOTECHNOLOGY. 2008. Available from: http://www.nature.com/naturebiotechnology
- Hummel M, Edelmann D, Kopp-Schneider A. Clustering of samples and variables with mixed-type data. PLoS One. 2017 Nov 1;12(11).
- 703 35. Zhang Z, Murtagh F, Poucke S Van, Lin S, Lan P. Hierarchical cluster analysis in clinical research with heterogeneous study population: Highlighting its visualization with R. Ann Transl Med. 2017 Feb 1;5(4).
- 706 36. Arora P, Deepali, Varshney S. Analysis of K-Means and K-Medoids Algorithm for Big Data. In: Physics Procedia. Elsevier B.V.; 2016. p. 507–12.
- Tos
   Liu Y, Li Z, Xiong H, Gao X, Wu J. Understanding of internal clustering validation measures. In: Proceedings IEEE International Conference on Data Mining, ICDM.
   2010. p. 911–6.
- 711 38. Zhao Q, Fränti P. WB-index: A sum-of-squares based index for cluster validity. Data Knowl Eng. 2014;92:77–89.

- 713 39. Hennig C. Cluster-wise assessment of cluster stability. Comput Stat Data Anal. 2007 Sep 15;52(1):258–71.
- 715 40. Van Buuren S, Groothuis-Oudshoorn K. Journal of Statistical Software mice:
- Multivariate Imputation by Chained Equations in R [Internet]. Vol. 45. 2011.

  Available from: http://www.jstatsoft.org/
- Farias AQ, Curto Vilalta A, Momoyo Zitelli P, Pereira G, Goncalves LL, Torre A, et
   al. Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in
   Latin America. Gastroenterology. 2023 Sep;165(3):696–716.
- 721 42. R Core Team. R: A language and environment for statistical. Vienna, Austria: R Foundation for Statistical Computing; 2021.
- Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision
   Medicine, AI, and the Future of Personalized Health Care. Vol. 14, Clinical and
   Translational Science. Blackwell Publishing Ltd; 2021. p. 86–93.
- 44. Kiselev VY, Andrews TS, Hemberg M. Challenges in unsupervised clustering of single-cell RNA-seq data. Vol. 20, Nature Reviews Genetics. Nature Publishing Group; 2019. p. 273–82.
- Qi R, Ma A, Ma Q, Zou Q. Clustering and classification methods for single-cell
   RNA-sequencing data. Vol. 21, Briefings in Bioinformatics. Oxford University
   Press; 2019. p. 1196–208.
- 732 46. Coombes CE, Liu X, Abrams ZB, Coombes KR, Brock G. Simulation-derived best practices for clustering clinical data. J Biomed Inform. 2021 Jun 1;118.
- Müller E, Günnemann S, Färber I, Seidl T. Discovering multiple clustering solutions:
   grouping objects in different views of the data. In: Proceedings International
   Conference on Data Engineering. 2012. p. 1207–10.
- Hu J, Pei J. Subspace multi-clustering: a review. Vol. 56, Knowledge and Information Systems. Springer London; 2018. p. 257–84.
- 739 49. Lu Y, Phillips CA, Langston MA. A robustness metric for biological data clustering algorithms. BMC Bioinformatics. 2019 Dec 24:20.
- Harville EW, Grady SK, Langston M, Juarez PJ, Vilda D, Wallace ME. The public health exposome and pregnancy-related mortality in the United States: a high-dimensional computational analysis. BMC Public Health. 2022 Dec 1;22(1).
- 51. Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R. Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver International. 2016 Jul;36(7):936–48.
- 747 52. Paternostro R, Jachs M, Hartl L, Simbrunner B, Scheiner B, Bauer D, et al. Diabetes
   748 impairs the haemodynamic response to non □ selective betablockers in compensated
   749 cirrhosis and predisposes to hepatic decompensation. Aliment Pharmacol Ther. 2023
   750 Jul 31;
- 751 53. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015 Feb;62(2):437–47.
- 754 54. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017 May;5(2):138–47.
- 755 55. Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro
   756 GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and
   757 comprehensive care in hepatic encephalopathy. Revista de Gastroenterología de
   758 México (English Edition). 2023 Apr;88(2):155–74.

## Figure Legends

Figure 1. Schematic overview of the different steps of ClustALL approach (best viewed in colour). ClustALL takes clinical variables as input. First, data complexity is reduced by grouping the features into a dendrogram, assessing the resulting depths, and using Principal Component Analysis (PCA) (green panel). The output is an embedding for each possible depth. Then, stratification is computed considering the combination of different distance measures, clustering techniques, and cluster numbers (K) (purple panel). In the final step, non-robust stratifications are filtered, and the centroids derived from computing Jaccard (coloured green squares) similarity among the robust stratifications (green squares) are considered the final representatives of the stratifications (red panel).

Figure 2. Summary of the outputs from the different steps of the ClustALL framework when applied to the PREDICT cohort (N=766). Input data comprised 74 clinical features with less than 30% missing values. The analysis utilized 1,000 imputed datasets. The Data Complexity Reduction step (green) was applied to 72 depths of the 1,000 imputed datasets. The Stratification Process step (purple) considered various clustering combinations resulting in 288 stratifications. After bootstrapping, 144 robust stratifications remained. Finally, in the Consensus-based Stratification step (red), five groups of robust stratifications (red squares) were identified, and the centroid was selected from each group as the final stratifications (red coloured squares).

Figure 3. Principal Component projection of the ClustALL robust stratifications based on the embedding associated with each stratification. (A-E). Low-dimension representation of the robust stratifications after applying the ClustALL framework to the PREDICT cohort. For each one of the 5 robust stratifications identified by ClustALL, the Principal Component Analysis of the Embeddings corresponding to the specific dendrogram depth associated with the stratification is shown. The x (Dim1) and y (Dim2) axes represent the first and second principal components respectively, which are linear combinations of the original variables. (F). The overlap between the clusters in stratifications 1 and 2 shows that stratification 1 is a subdivision of stratification 2.

Figure 4. Overview of the variables driving the ClustALL stratifications. (A). Heatmap with the minimal set of variables required to describe the 5 different stratifications, accounting for 25 out of 74 input variables. (B). Heatmaps of the minimal set of patient characteristics per stratification. The heatmap colour scale depends on the data type. In the case of binary variables, the value indicates the percentage of patients with such binary characteristics, e.g., the presence of Diabetes Mellitus. For continuous variables, the colour scale represents a scaled value from the highest cluster mean (100.0) to the lowest cluster mean (0.0), e.g., Albumin and CRP. Abbreviations: ASH = Acute Alcoholic-Steatohepatitis, AST = Aspartate aminotransferase, CL= Cluster, CRP = C-Reactive Protein, HE = Hepatic encephalopathy, HCC = Hepatocellular Carcinoma, INR = International normalized ratio, WBC = White blood cell counts.

Figure 5. Clinical overview of the AD-strat derived clusters in the PREDICT cohort. (A, B). Distribution of the highest predictive performance-related patient characteristics among AD-strat clusters; (A) categorical variables, (B) numerical variables. C) Cumulative incidence of ACLF (left) and death (right) according to the AD-strat clustering in PREDICT cohort considering 90 days after hospital admission, with the number of patients at risk per cluster (Transplantation counted as a competing risk to death). Abbreviations: AST = Aspartate aminotransferase, CRP = C- Reactive Protein, INR = International normalized ratio, WBC = White blood cell counts.

Figure 6. Reproducibility of the AD-strat model in the ACLARA cohort. (A) Distribution of the labels in the ACLARA cohort after applying the kNN model 1,000 times. (B) Proportion of patients


distributed in the 3 clusters in the PREDICT and the ACLARA cohorts. (C) Heatmap of patient characteristics per cluster in the ACLARA cohort. Bars on the right show the colour scale representing the proportion with each binary characteristic, such as diabetes. Continuous variables, such as bilirubin, represent a scaled value from the highest cluster mean (1.0) to the lowest cluster mean (0.0). (D) Cumulative incidence of ACLF (up) and death (down) according to the AD-strat clustering in ACLARA cohort considering 28 days after hospital admission, with the number of patients at risk per cluster (Transplantation counted as a competing risk to death). Abbreviations: AST = Aspartate aminotransferase, CRP = C- Reactive Protein, INR = International normalized ratio, WBC = White blood cell counts.


Figure 7. Distribution and transition of the AD-strat derived clusters at different visits in the PREDICT cohort. (A). Schematic representation of PREDICT study design. Two follow-up visit plans were defined according to the reported disease severity (CLIF-C AD-score) at hospital admission (red). The information about the occurrence of any adverse event (liver transplant, ACLF or death) during the whole visit plan or the absence of events at the end of the study was tracked (blue). (B) Sankey plots show the cluster label of each patient over the follow-up visits. The follow-up flows of patients with CLIF-C AD >= 50 at hospital admission (up) and CLIF-C AD <50 at hospital admission (down) are shown. The distribution of the patients assessed at each follow-up visit per cluster is shown as frequency and proportion on the top of the Sankey representations. The accumulated frequency and proportion of adverse events at each follow-up visit respecting the whole cohort (for CLIF-C AD >=50, n=486; for CLIF-C AD < 50, n=280) are shown on the bottom of the Sankey representations. Reported event/eos, shows the status of a patient at the "end of the study": patients with a reported event or patients with no reported event.


## Figure 1

#### 1. Data Complexity Reduction

## **ClustALL**







## B. PCA reductions

Embedding<sub>3</sub>

Embedding<sub>1</sub>

Embedding,

ndivio

## 2. Stratification Process

## For each embedding:

## Distance metric

- + Clustering Method
- Correlation
  - Gower

- H-Clust
- K-means
- K-medoids

## **Evaluation of the optimal number of clusters**

K ∈ 2, 3, 4, 5, 6 (WB-ratio, Dunn and Silhouette)

#### **Stratifications**

(Embedding + Distance + Clustering)

#### 3. Consensus-based Stratifications

Components

- Population-based robust stratifications by bootstrapping
- 2. Parameter-based robust stratifications





Figure 2



## Input Data (74 variables)


- Demographics
- Clinical examination and laboratory data
- Cirrhosis severity scores
- Medical history
- Lifestyle

(Features with >30% NAs excluded)

## 1. Data Complexity Reduction








## 72,000 Embeddings

## 2. Stratification Process



## 3. Consensus-based Stratifications





Figure 3



# Figure 4





Figure 5 Α Diabetes Mellitus Hepatic encephalopathy Number of Clinical Events No Yes No Yes 0.00 0.25 0.50 1.00 0.25 0.50 0.75 1.00 0.25 0.50 Number of Organ Dysfunctions Number of Precipitating Events Clusters 0 1 2 Cluster 1 Cluster 2 Cluster 3 0.25 0.75 0.00 0.50 1.00 0.25 0.50 0.75 0.00 1.00 В 50 60 70 80 90 100 Albumin (g/dL) 7 2.8 2.9 3.0 3.1 CRP (mg/L) Bilirubin (mg/dL) 20 25 30 35 AST (units/L) 2 4 Sodium (mEq/L) 33 134 135 136 137 138 INR 1.3 1.4 1.5 1.6 1.7 1.8 WBC (x10<sup>3</sup>/mm<sup>3</sup>) С **Cumulative incidence of ACLF Cumulative incidence of Death** 0.3 0.3 p < 0.0001p < 0.00010.2 0.2 < 0.001 p < 0.001p < 0.001p < 0.001 0.1 = 0.30.1 p = 0.030 0 30 60 90 30 60 90 Number at risk Number at risk 306 269 237 210 306 248 215 192 112 118 114 111 118 111 109 106 342 329 307 295 342 320 294 283 0 30 60 90 0 30 60 90 Days after Hospital Admission Days after Hospital Admission

Figure 6 В **ACLARA** 100 -Proportion of patients 75 **-Imputations** Clusters 1000 Cluster 1 50 -Cluster 2 500 Cluster 3 0 25 -0 -ACLARA PREDICT C D ACLARA **ACLARA** 0.20 Cumulative incidence of ACLF p < 0.001Diabetes Me 0.15 p < 0.001 Nº of precipitants p < 0.05 0.10 Nº of clinical events ΗE 0.05 INR 100 0.00 80 Bilirubin 10 Ö 20 28 60 Number at risk Albumin 40 185 158 143 133 Sodium 99 83 78 20 74 296 275 268 261 0 N° of Dysfunctions 10 20 Days after Hospital Admission 0 28 CRP **ACLARA WBC** Cumulative incidence of death 0.20 AST 0.15 p = 0.0032p < 0.01 0.10 < 0.05 0.05 0.00 Ö 10 20 28 Number at risk 185 172 160 148 99 94 88 83 296 286 280 273 10 20 Days after Hospital Admission Ö 28



# Figure 8

